Moving Beyond Amyloid in Alzheimer’s Therapeutics

April 18, 2023 A growing number of start-up companies are pursuing alternative strategies in drug development for patients with Alzheimer’s disease that bypass the beta amyloid hypothesis that has dominated the field for decades. Although the major manifestations of AD are global cognitive decline and loss of independent function, accessory symptoms include aberrant accumulation of…

Founders Keepers Podcast: Dr Sharon Rogers – Finding a cure for Alzheimer’s Disease with AmyriAD

#36 Dr Sharon Rogers – Finding a cure for Alzheimer’s Disease with AmyriAD February 17, 2023 AmyriAD is an LA-based clinical-stage biotech company working to advance effective therapies for the treatment of Alzheimer’s Disease, bringing together decades of experience with the singular goal of easing the devastation it causes. The Company’s lead drug candidate, AD101,…

LaBiotech.eu / Beyond Biotech Podcast: Talking about Alzheimer’s disease: current drugs, clinical trials, and the pipeline

Talking about Alzheimer’s disease: current drugs, clinical trials, and the pipeline February 9, 2023 In this wide-ranging podcast, Sharon L. Rogers, CEO of the biotech AmyriAD Therapeutics, covers her career studying Alzheimer’s, how the disease works, what her company is working on, lecanemab, and the future of Alzheimer’s research and treatments. Listen to the podcast…

BIOSPACE: FDA Made the Right Call on Lilly’s Donanemab, Some Experts Say

FDA Made the Right Call on Lilly’s Donanemab, Some Experts Say January 24, 2023 Thursday, the FDA rejected Eli Lilly’s Alzheimer’s disease candidate, donanemab, an investigational antibody to ameliorate the symptoms of Alzheimer’s disease (AD). While the news may have disappointed the company, some AD experts asserted the FDA’s actions were appropriate. What’s more, Lilly’s approach with donanemab is…